Astellas Pharma, Inc.

2-5-1 Nihonbashi-Honcho,
Chuo-Ku, 103-8411
Japan,
+81-03-3244-3271
www.astellas.com

Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia. Astellas was formed in 2005 and is based in Chuo-Ku, Japan.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (0.6/yr) # 4 - - - 1 2 7
vol $4.0B $476M $729M $5.2B
Sell (0.2/yr) # - - - 1 - - 1
vol $761M $761M
  8

Top M&A Advisors

Financial Deals
Join to Access.
Legal Deals
Sign-up to View
1
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest OSI Pharmaceuticals, Inc.
$4.0B (2010-06-09)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Astellas Pharma - Global Dermatology
$761M (2015-11-11)

According to our data here at Mergr, Astellas Pharma has acquired 7 companies, including 3 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.

Astellas Pharma’s largest acquisition to date was in 2010, when it acquired OSI Pharmaceuticals for $4.0B. It’s largest disclosed sale occurred in 2015, when it sold Astellas Pharma - Global Dermatology to LEO Pharma AS for $761M. Astellas Pharma has acquired in 4 different US states, and 3 countries. The Company’s most targeted sectors include life science (86%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 23 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Astellas Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 113K M&A Transactions
  • 123K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.